Search
Dexmedetomidine
go.drugbank.com/drugs/DB00633ApprovedInvestigationalVet approvedAn agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.
Sirna-027
go.drugbank.com/drugs/DB05896InvestigationalSirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular degeneration.
LIC-477
go.drugbank.com/drugs/DB05363ExperimentalLIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.
Apazunersen
go.drugbank.com/drugs/DB16981InvestigationalApazunersen is an antisense oligonucleotide designed to target and inhibit the expression of UBE3A-AS. It is being investigated for the treatment of Angelman Syndrome.[L46772]
Categories: Antisense Oligonucleotide Specific to the Antisense Transcript of UBE3AUlobetasol
go.drugbank.com/drugs/DB00596Approved[A215597] It is structurally related to [clobetasol].[A215597] Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.
Alfentanil
go.drugbank.com/drugs/DB00802ApprovedIllicitInvestigationalA short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analges...
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeQuinethazone
go.drugbank.com/drugs/DB01325ApprovedQuinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
LNP-nCoVsaRNA Vaccine
go.drugbank.com/drugs/DB15799ExperimentalLNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells. … The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly funded by UK Research and Innovation.
Cosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalOn December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the